The project has a four-year construction period followed by 15 years of operation and maintenance.

MUMBAI: BMC has set a March 2027 deadline for completing the 337 MLD Sewage Treatment Plant (STP) at Ghatkopar and directed officials to deploy additional manpower and speed up construction to meet the target.During a site inspection on Saturday, Additional Municipal Commissioner (Projects) Abhijit Bangar instructed officials to make optimum use of the current break in the monsoon to accelerate work and undertake multiple activities simultaneously. “Micro-planning is essential to ensure the project is completed within the stipulated time. If executed in a planned manner, it may even be possible to complete the project ahead of schedule,” he said.The Ghatkopar STP, being developed under the Mumbai Sewage Disposal Project, will have the capacity to treat 337 million litres of sewage a day (MLD) using Sequential Batch Reactor (SBR) technology. Of the total sewage treated, 170 MLD will undergo tertiary treatment before being discharged, significantly improving the quality of wastewater entering the sea.Bangar also reviewed the adjoining Ghatkopar pumping station upgrade, where civil and electrical works have achieved 85% physical progress. The project includes repairs to the pumping station building, replacement of mechanical equipment, laying of rising mains and installation of higher-capacity pumps. Officials have been directed to complete the pumping station by December 2026.The civic administration said the new STP is expected to improve coastal water quality and marine biodiversity while benefiting residents of Ghatkopar, Govandi, Mankhurd and Chembur.The project, however, poses significant engineering challenges as the existing sewage treatment plant must remain operational while the new facility is constructed. Before the new plant is commissioned, sludge accumulated in the existing treatment ponds has to be removed, treated and scientifically disposed of. The project site is also bounded by a creek, forest land and the eco-sensitive Thane Creek Flamingo Sanctuary, requiring careful execution.The contract for the project was awarded to JVPR Engineers Ltd in May 2022, with work commencing in July that year. The project has a four-year construction period followed by 15 years of operation and maintenance. SFC Environmental Technologies Pvt Ltd is the technology provider, while Tata Consulting Engineers Ltd is the consultant.Currently, the existing Ghatkopar plant provides only primary treatment—screening and degritting—before sewage is discharged into the creek. The new facility will provide full secondary treatment to 337 MLD of sewage, with tertiary treatment for nearly half of it, helping Mumbai meet stricter environmental standards.

Maharashtra FDA seized Aciloc drugs valued at Rs 2.45 crore (in pic: FDA Commissioner Tukaram Mundhe)

MUMBAI: In a major crackdown under the “Safe Food, Safe Medicines, Safe Maharashtra” campaign, the Maharashtra Food and Drug Administration (FDA) has seized stocks of Aciloc 150+ and Aciloc 300+ worth around Rs 2.45 crore.Following the crackdown, the department has ordered a complete market recall of the brand over concerns related to deceptive labelling and branding, news agency ANI reported.The action was initiated after a routine inspection in Amravati revealed that Cadila Pharmaceuticals Ltd., Ahmedabad, had been licensed for several years to manufacture.The company was licensed to market Aciloc 150 and Aciloc 300 containing Ranitidine as their Active Pharmaceutical Ingredient (API).However, the company recently launched Aciloc 150+ and Aciloc 300+, replacing Ranitidine with Famotidine, a completely different active pharmaceutical ingredient.Despite this significant change, the company continued with almost identical branding and label artwork, making only the addition of a “+” (Plus) sign to the product name before introducing the medicines into the market, ANI reported.The probe also found that the older Ranitidine-based Aciloc products and the newer Famotidine-based Aciloc Plus products were being sold simultaneously.Such similarity in the brand names could cause confusion among doctors, pharmacists and patients, increasing the possibility of the wrong medicine being dispensed or consumed.Regulatory guidelines clearly state that when the active ingredient or composition of a branded medicine is changed, the modified product should not be marketed under the same or a deceptively similar brand name.Following this, the FDA conducted inspections at the company’s Carrying & Forwarding Agent (CFA) warehouses in Pune, Nagpur and Bhiwandi (Thane).On July 9 and 10, 2026, the entire available stock of Aciloc 150+ and Aciloc 300+, valued at Rs 2,45,37,490, was prohibited from sale and distribution.Giving top priority to public health and patient safety, the FDA initiated this preventive action, observing that deceptively similar brand names could result in patients receiving the wrong medication.The company has also been instructed to immediately recall from the market the stocks of Aciloc 150, Aciloc 150 Plus, Aciloc 300 and Aciloc 300 Plus.Commenting on the action, FDA commissioner Tukaram Mundhe said, “Any confusion caused by a medicine’s brand name among patients, doctors, or pharmacists, leading to the dispensing of the wrong medicine, is a matter of grave public health concern.”“Compliance with regulations governing drug branding, labelling, and marketing, while ensuring patient safety, must remain paramount. Safe medicines are a fundamental right of every citizen, and safeguarding that right is our highest responsibility,” he added.The administration has also issued an advisory asking citizens and medical professionals to verify both the brand name and the active pharmaceutical ingredient before prescribing, dispensing or consuming any medicine.The administration has further appealed to citizens to immediately inform the FDA if they face any confusion because of similar medicine names or come across any suspicious medicines.Further investigation is underway, and suitable legal action will be initiated under the Drugs and Cosmetics Act, 1940, and the rules framed thereunder based on the findings, officials said.(With agency inputs)

A Mumbai woman’s unborn baby received an anti-cancer drug to shrink heart tumours (AI-generated image used for representational purposes)

For 38-year-old Jogeshwari resident Sevanti (name changed), reaching the 24th week of pregnancy after three early miscarriages felt like a victory.Then came devastating news: her unborn baby had five growing tumours in the heart and nodules in the brain, leaving doctors uncertain if the foetus would survive.Determined to have the baby, she refused an amniocentesis test that would confirm the underlying genetic disorder and instead urged doctors at Wadia Hospital in Parel to focus on saving her child.Doctors put Sevanti on an oral anti-cancer drug called Everolimus for four weeks to “shrink” the tumours in the foetus.On June 18, Sevanti gave birth to a 2.5-kg boy who has already undergone two heart scans. “The tumours shrank before his birth itself and don’t seem to be growing after his birth,” said foetal cardiologist Dr Shreepal Jain.

We have come so far and will carry in happily: Mom

Docs: We expect boy’s tumours to continue regressing and disappear as he grows older

When Jogeshwari’s Sevanti (name changed) found out her unborn baby had five tumours in the heart and nodules in the brain, she said she told the doctors, “Knowing the cause wouldn’t have changed my mind about having the baby, so why waste time?”The hospital’s newly formed foetal medicine team suspected the foetus had tuberous sclerosis, a genetic disorder often associated with multiple rhabdomyomas (heart tumours) and brain nodules.The oral anti-cancer drug Everolimus given to her for four weeks to “shrink” the tumours worked, “and we prolonged her pregnancy till the 36th week before delivering the baby,” said obstetrician Dr Pooja Bandekar and foetal medicine specialist Dr Vandana Bansal, who were treating her since the 20th week of pregnancy.On June 18, Sevanti gave birth to a 2.5 kg boy. “The tumours shrank before his birth itself and don’t seem to be growing after his birth. We expect them to disappear as he grows older,” said foetal cardiologist Dr Shreepal Jain.Dr Jain said one of the tumours grew large enough to obstruct blood flow from the foetal heart. The team reviewed published reports on the use of Everolimus during pregnancy before deciding to administer it to the mother so it could cross the placenta and reach the foetus. (Everolimus is also given to neonates in whom the cardiac rhabdomyomas are detected after birth. )The treatment required close monitoring because Everolimus can significantly raise cholesterol levels. Sevanti underwent regular blood tests to monitor drug levels and cholesterol while weekly scans tracked the baby’s condition.Two post-birth echocardiograms showed the tumours shrank before delivery and have not grown since. “The tumours shrank before his birth and don’t seem to be growing after birth. We expect them to continue regressing as he grows older,” said Dr Jain.Wadia Hospital CEO Dr Minnie Bodhanwala said this is possibly Mumbai’s first reported case in which maternal treatment with Everolimus was successfully used to shrink foetal cardiac rhabdomyomas. “A similar case was previously reported from Hyderabad,” she said.Dr Bansal said multiple cardiac rhabdomyomas are strongly associated with tuberous sclerosis complex, a genetic disorder affecting the brain, skin, kidneys and other organs. Because the baby also has brain nodules, he could develop seizures later in life, but these can usually be managed with medication, said Dr Bandekar.Independent foetal medicine specialist Dr Chander Lulla, who was not involved in the treatment, said cardiac rhabdomyomas are rare and Everolimus has emerged as an effective option in selected cases.Sevanti is optimistic. “We have come so far and will carry on happily,” she said.

Police said preliminary investigation indicates that many other citizens may also have been cheated in a similar manner

Mumbai: The city crime branch arrested a Jaipur businessman and an impostor who impersonated an IPS officer in a fresh case of cheating after a Gujarat businessman lodged a complaint alleging that the accused cheated him of Rs 16 lakh by posing as a Deputy Commissioner of Police (DCP) and promising to recover money allegedly owed to him from one builder.The crime branch last month arrested three persons, Mohammed Guas Khatib alias Raj Khatib, his son Mashab Khatib and Shahid Kapadia, red-handed from a three-star hotel while trying to cheat a person seeking a loan.Unit 1 of the crime branch on Friday arrested Rajasthan businessman Rajesh Bedsingh Choudhary, 46, and Mohammed Khatib, who was already in custody in connection with a similar cheating case.The fresh complaint was filed by Sikander Kothari, who runs an OTT platform, and alleged that he first met Rajesh Chaudhary and Naveen Sharma at Marine Drive in 2024. They allegedly introduced Khatib as a serving DCP in the Mumbai Police. Investigators said Khatib reinforced the deception by showing photographs of himself in a police uniform bearing stars and insignia and claimed he could recover the complainant’s investment from builder Kamal Sadhwani through his influence in the police force. Kothari alleged that he paid Rs 98 lakh to Jadhwani and booked a flat, but he neither got the flat nor his money back.Believing the claims, Kothari allegedly paid Rs 4 lakh in cash, handed over an Apple iPhone worth Rs 1.3 lakh, and later made several additional cash and online payments. The total amount allegedly cheated is Rs 15,90,532.Police said Khatib also claimed that money and expensive gifts were required to “please” police officers handling the matter. Despite repeated assurances, the promised work was never completed.During the investigation, crime branch officers recorded the statement of a retired police inspector who runs a tailoring shop. The witness allegedly stated that Khatib got a khaki police uniform stitched from his shop with provisions for police stars and insignia. Investigators seized the tailor’s receipt book and collected digital payment records, which allegedly show that payment for the uniform was made through the CRED account of Khatib’s son.Police said preliminary investigation indicates that many other citizens may also have been cheated similarly, and hence requested the victims to come forward and register a complaint.